Security Snapshot

NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR 0.12 per share (NAMS) Institutional Ownership

CUSIP: N62509109

13F Institutional Holders and Ownership History from Q4 2022 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

138

Shares (Excl. Options)

106.38MFull value: 106,381,199 · shares · 30 Sep 2026

Price

$24.32

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+6,114,728
Value change
+$120,926,876
Number of holders
138
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
123,305,030
SEC-reported price per share
$21.50
Insider filing price
$21.50
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • NAMS - NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR 0.12 per share is tracked under CUSIP N62509109.
  • 138 institutions reported positions in Q3 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 194 to 138 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $4.13BFull value: $4,131,839,683 · USD · 30 Jun 2026
    to
    $2.58BFull value: $2,584,170,683 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 138 institutions filings for Q3 2026.

Open SEC evidence

Security key

N62509109

13F reference period

Q3 2026

13F holders

138

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
NAMS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $262,454,757 +$24,597,570 12,207,198 +10% RA Capital Management, L.P. 30 Sep 2026
Capital World Investors 10% +19% $460,111,232 +$89,303,892 12,188,377 +24% Capital World Investors 29 May 2026
FMR LLC 10% +13% $265,943,062 +$35,678,767 11,941,763 +15% FMR LLC 30 Sep 2026
Frazier Life Sciences X, L.P. 8.7% +12% $269,987,402 +$46,627,382 10,424,224 +21% Frazier Life Sciences Public Fund, L.P. 18 Sep 2026
Forbion Capital Fund IV Cooperatief U.A. 8.3% -12% $223,140,090 -$30,222,313 9,316,914 -12% ForGrowth NAP B.V. 26 Sep 2025
Janus Henderson Group Ltd. 7.5% $199,813,010 8,972,295 JANUS HENDERSON GROUP Ltd. 30 Sep 2026
VIKING GLOBAL INVESTORS LP 3.7% -40% $144,476,598 -$95,375,616 4,203,567 -40% VIKING GLOBAL INVESTORS LP 31 Dec 2025
BCLS II Investco, LP 1.8% -59% $74,671,230 -$120,221,675 2,059,896 -62% BCLS Fund III Investments, LP 12 May 2026
As of 30 Sep 2026, 138 institutional investors reported holding
106.38MFull value: 106,381,199 · shares · 30 Sep 2026
shares of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR 0.12 per share (NAMS). This represents 86% of the company’s total
123.31MFull value: 123,305,030 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
76%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 15% 18,988,902 11% $461,810,097
Capital World Investors 10% 12,881,484 0.04% $313,277,691
RA CAPITAL MANAGEMENT, L.P. 7.7% 9,550,191 2.3% $232,260,645
Janus Henderson Group Ltd. 7.3% 8,972,293 0.09% $218,258,187
FCPM III SERVICES B.V. 6.9% 8,490,353 19% $206,485,385
DEERFIELD MANAGEMENT COMPANY, L.P. 3.5% 4,254,314 1.6% $103,464,916
Bain Capital Life Sciences Investors, LLC 3.1% 3,806,559 6.2% $92,575,514
Orbis Allan Gray Ltd 3.1% 3,760,821 0.3% $91,463,166
Duquesne Family Office LLC 2.7% 3,357,146 2% $81,646,000
VIKING GLOBAL INVESTORS LP 2% 2,463,911 0.18% $59,922,316
Medicxi Ventures Management (Jersey) Ltd 1.8% 2,182,339 42% $53,074,484
GOLDMAN SACHS GROUP INC 1.6% 1,984,732 0.01% $48,268,682
MAVERICK CAPITAL LTD 1.5% 1,855,630 0.36% $45,128,922
Capital International Investors 1.5% 1,842,170 0.01% $44,801,574
ALLIANCEBERNSTEIN L.P. 1.2% 1,440,944 0.01% $35,043,758
Aberdeen Group plc 0.96% 1,184,091 0.04% $28,797,093
TWO SIGMA INVESTMENTS, LP 0.92% 1,135,081 0.02% $27,605,170
Castle Hook Partners LP 0.71% 873,367 0.17% $21,240,285
Polar Capital Holdings Plc 0.7% 866,109 0.06% $21,063,771
Woodline Partners LP 0.61% 752,689 0.06% $18,305,396
First Turn Management, LLC 0.57% 702,396 2.3% $17,082,271
NWI MANAGEMENT LP 0.57% 702,000 0.96% $17,072,640
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.57% 700,000 0.02% $17,024,000
Rock Springs Capital Management LP 0.5% 613,942 0.8% $14,931,069
KENNEDY CAPITAL MANAGEMENT LLC 0.44% 547,629 0.25% $13,318,337

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
16
Headline period
Q3 2026
Rows shown
1-16 of 16
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 106,381,199 $2,584,170,683 +$120,926,876 $24.32 138
2026 Q2 121,990,566 $4,131,839,683 -$68,037,466 $33.89 194
2026 Q1 123,556,581 $3,956,276,151 +$129,847,431 $32.01 170
2025 Q4 119,332,967 $4,186,690,487 -$35,445,065 $35.08 188
2025 Q3 120,390,588 $3,423,902,136 +$122,882,388 $28.44 135
2025 Q2 116,368,291 $2,107,516,504 +$92,203,105 $18.11 130
2025 Q1 111,177,846 $2,278,669,708 +$247,823,372 $20.47 126
2024 Q4 98,611,632 $2,534,320,573 +$569,548,998 $25.70 130
2024 Q3 77,090,356 $1,279,730,929 +$65,939,934 $16.60 100
2024 Q2 72,010,250 $1,383,367,935 -$7,907,090 $19.21 90
2024 Q1 72,152,341 $1,706,357,479 +$242,490,357 $23.65 76
2023 Q4 61,897,680 $691,396,295 -$81,202 $11.17 32
2023 Q3 50,178,896 $464,099,871 +$5,440,463 $9.25 35
2023 Q2 48,833,993 $580,635,231 +$184,129,037 $11.89 29
2023 Q1 33,346,896 $444,858,187 +$689,119 $13.26 19
2022 Q4 33,516,836 $362,234,361 +$362,234,361 $10.90 14
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .